[go: up one dir, main page]

WO2003044226A3 - Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder - Google Patents

Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder Download PDF

Info

Publication number
WO2003044226A3
WO2003044226A3 PCT/EP2002/013265 EP0213265W WO03044226A3 WO 2003044226 A3 WO2003044226 A3 WO 2003044226A3 EP 0213265 W EP0213265 W EP 0213265W WO 03044226 A3 WO03044226 A3 WO 03044226A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferative
lymphoid cell
analysis
nucleic acids
proliferative disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/013265
Other languages
French (fr)
Other versions
WO2003044226A2 (en
Inventor
Matthias Burger
Charles Caldwell
Buelent Genc
Evelyne Becker
Sabine Maier
Inko Nimmrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenomics AG
Original Assignee
Epigenomics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10164501A external-priority patent/DE10164501A1/en
Application filed by Epigenomics AG filed Critical Epigenomics AG
Priority to AU2002352143A priority Critical patent/AU2002352143A1/en
Priority to EP02787817A priority patent/EP1451354A2/en
Publication of WO2003044226A2 publication Critical patent/WO2003044226A2/en
Publication of WO2003044226A3 publication Critical patent/WO2003044226A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in the differentiation, diagnosis, treatment and/or monitoring of lymphoid cell proliferative disorders, or the predisposition to lymphoid cell proliferative disorders.
PCT/EP2002/013265 2001-11-23 2002-11-25 Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder Ceased WO2003044226A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002352143A AU2002352143A1 (en) 2001-11-23 2002-11-25 Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder
EP02787817A EP1451354A2 (en) 2001-11-23 2002-11-25 Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10157491 2001-11-23
DE10157491.6 2001-11-23
DE10164501A DE10164501A1 (en) 2001-11-23 2001-12-28 Methods and nucleic acids for the analysis of a lymphoid cell division disorder
DE10164501.5 2001-12-28

Publications (2)

Publication Number Publication Date
WO2003044226A2 WO2003044226A2 (en) 2003-05-30
WO2003044226A3 true WO2003044226A3 (en) 2004-03-11

Family

ID=26010632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/013265 Ceased WO2003044226A2 (en) 2001-11-23 2002-11-25 Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder

Country Status (3)

Country Link
EP (1) EP1451354A2 (en)
AU (1) AU2002352143A1 (en)
WO (1) WO2003044226A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096905B2 (en) * 2012-02-23 2015-08-04 Medical Diagnostic Laboratories, Llc Detecting DNA methylation of BCL2, CDKN2A and NID2 genes to predict bladder cancer in humans

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693468A1 (en) 2005-02-16 2006-08-23 Epigenomics AG Method for determining the methylation pattern of a polynucleic acid
US7932027B2 (en) 2005-02-16 2011-04-26 Epigenomics Ag Method for determining the methylation pattern of a polynucleic acid
PT1871912E (en) 2005-04-15 2012-05-25 Epigenomics Ag Method for determining dna methylation in blood or urine samples
GB2435882A (en) * 2006-03-09 2007-09-12 Bioinvent Int Ab Detection and treatment of mantle cell lymphoma
WO2007137597A1 (en) * 2006-05-26 2007-12-06 Cnr Consiglio Nazionale Delle Ricerche Tests for detection of hot spot mutations and methylation of retinoblastoma-like 2 gene (rbl2) as diagnostic and prognostic markers of tumors
EP2134873B1 (en) 2007-03-29 2015-05-06 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8299237B2 (en) 2007-08-30 2012-10-30 Hadasit Medical Research Services & Development Ltd. Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders
US8242243B2 (en) 2008-05-15 2012-08-14 Ribomed Biotechnologies, Inc. Methods and reagents for detecting CpG methylation with a methyl CpG binding protein (MBP)
MX2011009736A (en) 2009-03-15 2012-06-01 Ribomed Biotechnologies Inc Abscription based molecular detection.
EP3132055A2 (en) * 2014-04-14 2017-02-22 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077668A (en) * 1993-04-15 2000-06-20 University Of Rochester Highly sensitive multimeric nucleic acid probes
WO2001007647A2 (en) * 1999-07-26 2001-02-01 Epigenomics Ag Method for relative quantization of methylation of cytosin-type bases in dna samples
WO2002077272A2 (en) * 2001-03-26 2002-10-03 Epigenomics Ag Methods and nucleic acids for the analysis of hematopoietic cell proliferative disorders
WO2003052135A2 (en) * 2001-12-14 2003-06-26 Epigenomics Ag Method and nucleic acids for the analysis of a lung cell proliferative disorder

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077668A (en) * 1993-04-15 2000-06-20 University Of Rochester Highly sensitive multimeric nucleic acid probes
WO2001007647A2 (en) * 1999-07-26 2001-02-01 Epigenomics Ag Method for relative quantization of methylation of cytosin-type bases in dna samples
WO2002077272A2 (en) * 2001-03-26 2002-10-03 Epigenomics Ag Methods and nucleic acids for the analysis of hematopoietic cell proliferative disorders
WO2003052135A2 (en) * 2001-12-14 2003-06-26 Epigenomics Ag Method and nucleic acids for the analysis of a lung cell proliferative disorder

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BAUR A S ET AL: "Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas.", BLOOD. UNITED STATES 1 SEP 1999, vol. 94, no. 5, 1 September 1999 (1999-09-01), pages 1773 - 1781, XP002255681, ISSN: 0006-4971 *
GARCIA-MANERO G ET AL: "CPG ISLAND METHYLATION PROFILE IN ACUTE LYMPHOCYTIC LEUKEMIA (ALL)", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 96, no. 11, PART 1, 16 November 2000 (2000-11-16), pages 102A, XP009010440, ISSN: 0006-4971 *
GARCIA-MANERO GUILLERMO ET AL: "DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES JUL 2002, vol. 8, no. 7, July 2002 (2002-07-01), pages 2217 - 2224, XP002255684, ISSN: 1078-0432 *
KANTHARIDIS P ET AL: "Altered Methylation of the Human MDR1 Promoter is Associated with Aquired Multidrug Resistance", CLINICAL CANCER RESEARCH, vol. 3, pages 2025 - 2032, XP001155344 *
MODEL F ET AL: "Feature selection for DNA methylation based cancer classification.", BIOINFORMATICS (OXFORD, ENGLAND) ENGLAND 2001, vol. 17 Suppl 1, 2001, pages S157 - S164, XP001154594, ISSN: 1367-4803 *
SHANNON B A ET AL: "Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features.", CANCER LETTERS. IRELAND 10 JUN 2001, vol. 167, no. 1, 10 June 2001 (2001-06-10), pages 91 - 97, XP002255680, ISSN: 0304-3835 *
TADA Y ET AL: "MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES DEC 2000, vol. 6, no. 12, December 2000 (2000-12-01), pages 4618 - 4627, XP002255679, ISSN: 1078-0432 *
TAYLOR J M ET AL: "The diagnositc significance of Myf-3 hypermethylation in malignant lymphoproliferative disorders.", LEUKEMIA: OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. ENGLAND APR 2001, vol. 15, no. 4, April 2001 (2001-04-01), pages 583 - 589, XP001154596, ISSN: 0887-6924 *
VAN DEN HEUVEL-EIBRINK M M ET AL: "MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7.", LEUKEMIA: OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. ENGLAND MAR 2001, vol. 15, no. 3, March 2001 (2001-03-01), pages 398 - 405, XP002255678, ISSN: 0887-6924 *
WADA F ET AL: "5' CPG ISLAND DEMETHYLATION IS ASSOCIATED WITH TRANSCRIPTIONAL ACTIVATION OF THE HUMAN MULTIDRUG-RESISTANCE 1 (MDR1) GENE IN HUMAN TUMORS", PROCEEDINGS OF THE 88TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN DIEGO, APR. 12 - 16, 1997, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, AACR, US, vol. 38, March 1997 (1997-03-01), pages 480, XP001160788 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096905B2 (en) * 2012-02-23 2015-08-04 Medical Diagnostic Laboratories, Llc Detecting DNA methylation of BCL2, CDKN2A and NID2 genes to predict bladder cancer in humans

Also Published As

Publication number Publication date
EP1451354A2 (en) 2004-09-01
WO2003044226A2 (en) 2003-05-30
AU2002352143A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2002077272A3 (en) Methods and nucleic acids for the analysis of hematopoietic cell proliferative disorders
WO2002002808A3 (en) Method and nucleic acids for the analysis of astrocytomas
WO2003072821A3 (en) Method and nucleic acids for the analysis of a colon cell proliferactive disorder
WO2003052135A8 (en) Method and nucleic acids for the analysis of a lung cell proliferative disorder
WO2004035803A3 (en) Method and nucleic acids for the treatment of breast cell proliferative disorders
WO2004020662A3 (en) Method and nucleic acids for the analysis of breast cell proliferative disorders
WO2001077377A3 (en) Diagnosis of diseases associated with dna replication by assessing dna methylation
WO2005059172A3 (en) Method and nucleic acids for the improved treatment of breast cell proliferative disorders
WO2001068911A8 (en) Diagnosis of diseases associated with the cell cycle
WO2003044226A3 (en) Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder
WO2003014388A3 (en) Method and nucleic acids for the analysis of colon cancer
WO2002103042A3 (en) Method and nucleic acids for the differentiation of prostate tumors
WO2002046454A3 (en) Diagnosis of diseases associated with angiogenesis by determining the methylation of genes associated with angiogenesis
WO2002036814A3 (en) Diagnosis of diseases associated with cdk4 by determining the methylation state of the cdk4
WO2002012554A3 (en) Diagnosis of diseases which are associated with cd24
WO2002103041A3 (en) Method and nucleic acids for the differentiation of prostate and renal carcinomas
WO2002036604A3 (en) Diagnosis of diseases associated with the human c-mos gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002787817

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002787817

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002787817

Country of ref document: EP